|1.||Pascual, J: 9 articles (09/2008 - 07/2000)|
|2.||Cabarrocas, X: 9 articles (09/2006 - 01/2001)|
|3.||Pascual, Julio: 8 articles (10/2010 - 01/2002)|
|4.||Mathew, Ninan T: 8 articles (03/2009 - 01/2002)|
|5.||Allais, Gianni: 7 articles (05/2014 - 06/2010)|
|6.||Benedetto, Chiara: 7 articles (05/2014 - 06/2010)|
|7.||Goadsby, P J: 7 articles (12/2011 - 09/2003)|
|8.||Omboni, Stefano: 6 articles (01/2015 - 06/2011)|
|9.||Bussone, Gennaro: 6 articles (05/2014 - 06/2010)|
|10.||Finlayson, Gary: 6 articles (03/2009 - 02/2007)|
|1.||Migraine Disorders (Migraine)
01/01/2005 - "Trials assessing the efficacy of almotriptan over multiple attacks show that this agent is associated with a consistent and persistent response, not differing from the first to the last attack, an important property for a medication used to treat a chronic condition such as migraine. "
03/01/2010 - "Thus, the excellent efficacy and tolerability profile of almotriptan administered early in a migraine attack indicate that it may be a first-line treatment option in this common, underdiagnosed and undertreated disorder."
10/01/2007 - "Almotriptan should, therefore, not only be considered as first-line therapy for acute migraine but should also be considered for patients who are not satisfied with or not receiving optimal relief from their current acute therapy."
01/01/2002 - "Almotriptan was effective in animal models predictive of anti-migraine activity in humans and had a good safety profile in animal studies. "
02/01/2014 - "Few studies have been published to demonstrate tolerability and efficacy of almotriptan in adolescents and children with migraine, particularly in the first years of life, though preliminary results are favorable. "
03/01/2011 - "Given the large sample size, a sub-analysis was planned to ascertain whether any patient characteristics/behaviors might help predict/explain the responses observed in this study, which demonstrated that almotriptan administered early when pain was mild significantly improved pain-related outcomes compared with non-early/non-mild treatment. "
10/01/2008 - "Rates for sustained pain relief also were significantly greater with almotriptan 6.25 mg (67.2%), 12.5 mg (66.9%), and 25 mg (64.5%) than with placebo group (52.4%), P < .01 for the 6.25- and 12.5-mg doses and P < .05 for the 25-mg dose. "
09/01/2008 - "Almotriptan was effective in both cohorts with a consistent trend in favour of the efficacy of almotriptan in TN patients, notably for sustained pain freedom (SPF) and SPF plus no adverse events. "
10/01/2010 - "A secondary finding in these trials was that patients who took almotriptan early, when the pain was still mild, achieved better outcomes. "
04/01/2002 - "In 2 of the studies, patients with moderate or severe baseline pain used significantly less rescue medication in the almotriptan groups compared with placebo. "
04/01/2008 - "Studies of almotriptan in a variety of early intervention paradigms demonstrate significant improvements in efficacy and further improved tolerability compared with standard treatment of headaches of at least moderate severity. "
02/01/2007 - "The main reason for preference for one or the other triptan was efficacy: 43% of patients preferring almotriptan gave faster headache relief as the reason and 34% cited faster return to normal activities. "
01/01/2005 - "Early treatment (within 1 h) of moderate to severe headaches with almotriptan also improves outcomes. "
01/01/2004 - "Recurrence of headaches within 24 h is low with almotriptan (<22%). "
11/01/2003 - "A second dose of almotriptan 12.5 mg could be taken if head pain recurred within 24 hours of the initial dose. "
03/01/2009 - "The presence of AAS, which may indicate an early phase of allodynia, did not influence the efficacy of almotriptan therapy."
03/01/2009 - "To evaluate the relationship between treatment outcomes and allodynia-associated symptoms (AAS) at the time of treatment with almotriptan. "
12/01/2011 - "The impact of allodynia on the efficacy of almotriptan when given early in migraine: data from the "Act when mild" study."
09/01/2010 - "Almotriptan efficacy in migraine with allodynia: a rebuttal to Burstein and Jakubowski's critique of Schoenen et al."
10/01/2009 - "Almotriptan efficacy in migraine with allodynia: a critique of Schoenen et al."
12/20/2000 - "Almotriptan is a new 5-HT(1B/1D) receptor agonist effective for treating acute migraine attacks with or without aura. "
02/01/2008 - "These are post hoc analyses of data from the AXERT Early miGraine Intervention Study (AEGIS), a multicenter, double-blind, parallel-group trial that evaluated adults with IHS-defined migraine with and without aura. "
05/01/2001 - "Almotriptan was safe and well tolerated in nearly all adult patients with migraine, with and without aura, enrolled in these studies. "
04/01/2006 - "Fifteen patients aged 11-17 with a history of migraine with or without aura were treated with almotriptan. "
11/01/2003 - "This was a post hoc analysis derived from an open-label, multicenter, long-term study of the safety, tolerability, and efficacy of almotriptan 12.5 mg. Patients who met International Headache Society criteria for migraine with or without aura were eligible. "
|8.||Caffeine (No Doz)